| Website | nlvpartners.com |
| Phone | 212-213-0006, ext. 27 |
| info@nlvpartners.com | |
| Employees | |
| Founded | 2005 |
| Description | Health-Care Focused VC Firm |
| Life Sciences Fund, 10/07 | $450M |
New Leaf Venture Partners is a venture capital firm that invests primarily in healthcare technology. The company typically focuses on later stage biopharmaceutical products, early stage medical devices, and laboratory infrastructure technologies.
The New Leaf Ventures (NLV) team has been built over a decade, originating within Sprout Group, the venture capital affiliate of Credit Suisse First Boston. Sprout Group was formed in 1969 and has historically been one of the leading venture capital firms in the country. The team started to invest in healthcare technology in 1993 and since then, has become a leading venture investor in that sector. In 2005, the entire healthcare technology team of Sprout spun out into NLV.
| Company | Date | Round | Size | Participants |
| Treato | 4/13 | Series B | $14.5M | 3 |
| iRhythm Technologies | 4/13 | Series D | $16M | 4 |
| Aviir | 2/13 | Series F | $10M | 4 |
| Versartis | 1/13 | Series C | $25M | 4 |
| Pearl Therapeutics | 11/12 | Series D | $65M | 4 |
| Advanced Cell Diagnostics | 11/12 | Series B | $12M | 2 |
| Principia BioPharma | 10/12 | Series A | $12.5M | 5 |
| ReShape Medical | 10/12 | Series C | $15M | 3 |
| IlluminOss Medical | 9/12 | Series C | $28M | 9 |
| Karus Therapeutics | 9/12 | Series B | $7.6M | 4 |
| Oxford Immunotec | 6/12 | Venture Round | $28M | 8 |
| Awarepoint | 6/12 | Venture Round | $14M | 7 |
| BioRelix | 3/12 | Venture Round | $2.56M | 4 |
| Truveris | 2/12 | Series B | $10M | 4 |
| Aviir | 12/11 | Series E | $10M | 4 |
| CardioKinetix | 9/11 | Series E | $44M | 4 |
| Neuronetics | 5/11 | Series E | $30M | 8 |
| iRhythm Technologies | 5/11 | Series C | $15M | 3 |
| Synageva BioPharma | 3/11 | Venture Round | $25M | 4 |
| Versartis | 2/11 | Series B | $21M | 3 |
| Chimerix | 2/11 | Series F | $45M | 8 |
| Spine Wave | 2/11 | Series E | $17.5M | 5 |
| Spiracur | 2/11 | Venture Round | $35M | 5 |
| WorldHeart | 10/10 | Venture Round | $25.3M | 3 |
| Pearl Therapeutics | 10/10 | Series C | $69M | 3 |
| Convergence Pharmaceuticals | 10/10 | Series A | $35.4M | 3 |
| Relypsa | 9/10 | Series B | $70M | 6 |
| Intarcia Therapeutics | 9/10 | Series B | $5M | 3 |
| Artisan Pharma | 7/10 | Series C | $3M | 5 |
| Altura Medical | 6/10 | Series A | $20M | 3 |
| Oxford Immunotec | 5/10 | Series D | $26M | 7 |
| Aureon Laboratories | 4/10 | Series D | $7M | 4 |
| Pearl Therapeutics | 3/10 | Series C | $15M | 3 |
| Tioga Pharmaceuticals | 2/10 | Series A | $18M | 4 |
| Aviir | 1/10 | Debt | $4.2M | 3 |
| Afferent Pharmaceuticals | 12/09 | Series A | $23M | 4 |
| Neuronetics | 10/09 | Series D | $30M | 7 |
| Synageva BioPharma | 10/09 | Series F | $12M | 5 |
| XDx | 10/09 | Venture Round | $14.4M | 7 |
| Direct Flow Medical | 10/09 | Series C | $40M | 7 |
| Presidio Pharmaceuticals | 7/09 | Venture Round | $27M | 1 |
| Interlace Medical | 7/09 | Series C | $20M | 3 |
| Spiracur | 6/09 | Series B | $20.3M | 3 |
| VaxInnate | 6/09 | Series D | $30M | 7 |
| Visiogen | 5/09 | Series D | $40M | 7 |
| ReShape Medical | 2/09 | Series B | $20M | 3 |
| Pearl Therapeutics | 7/08 | Series A | $18M | 4 |
| Concert Pharmaceuticals | 4/08 | Series C | $37M | 12 |
| Stromedix | 4/08 | Series B | $25M | 5 |
| Oriel Therapeutics | 11/07 | Venture Round | $26.5M | 1 |
| Relypsa | 10/07 | Series A | $33M | 6 |
| Aviir | 10/07 | Series B | $11.3M | 3 |
| ReShape Medical | 8/07 | Series A | $3M | 2 |
| BioRelix | 6/07 | Series A | $25.8M | 6 |
| Intarcia Therapeutics | 3/07 | Series A | 5 | |
| Transcept Pharmaceuticals | 3/07 | Series D | $40M | 8 |
| Concert Pharmaceuticals | 11/06 | Series B | $48.5M | 8 |
| VaxInnate | 10/06 | Series C | $40M | 6 |
| Artisan Pharma | 9/06 | Series A | $39M | 5 |
| Tioga Pharmaceuticals | 1/06 | Series A | $24M | 3 |
